Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.[1][2][3][4]

The Phase 2b/3 adaptive trial (SEPSIS-ACT) was terminated in February 2018 for futility. The trial was halted prior to the initiation of the arm for the highest dosing regimen of 5.0 ng/kg/min.[5]

References

  1. ^ Levin JI (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2.
  2. ^ Vincent JL (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2.
  3. ^ Vincent JL (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3.
  4. ^ Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, et al. (June 2011). "Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension". The Journal of Pharmacology and Experimental Therapeutics. 337 (3): 786–96. doi:10.1124/jpet.111.178848. PMID 21411496. S2CID 576654.
  5. ^ Clinical trial number NCT02508649 for "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial" at ClinicalTrials.gov